MECOM and myelodysplastic syndrome: A recent systematic review and meta-analysis documented 21 genotoxicity events following treatment with γRV vector across seven clinical trials for primary immunodeficiency, the majority attributed to trans-activation of LMO2 (nine patients) or MDS-EVI1 complex (six patients) [20].